More info
Active ingredients
Choline alfoscerat
Release form
Capsules
Composition
Active ingredient: Choline alfoscerate (Choline alfoscerate) Concentration of the active substance (mg): 400
Pharmacological effect
Cholinomimetic central action, which contains 40.5% of metabolically protected choline (metabolic protection contributes to the release of choline in the brain). When ingested, it is broken down by the action of enzymes on choline and glycerophosphate: choline is involved in the biosynthesis of acetylcholine, one of the main mediators of nervous excitation; glycerophosphate is a precursor of phospholipids (phosphatidylcholine) of the neuronal membrane. The drug provides the synthesis of acetylcholine and phosphatidylcholine in neuronal membranes, improves blood flow and enhances metabolic processes in the central nervous system, activates the reticular formation; increases the linear velocity of blood flow on the side of traumatic brain damage, contributes to the normalization of the spatial-temporal characteristics of the spontaneous bioelectric activity of the brain; It has a positive effect on the cognitive and behavioral reactions of patients with vascular diseases of the brain. The drug improves brain function by acting on the pathogenetic factors of involutional psychoorganic syndrome, changes the phospholipid composition of neuronal membranes and reduces cholinergic activity. Dose-dependent stimulates the release of acetylcholine, participating in the synthesis of phosphatidylcholine (membrane phospholipid), improves synaptic transmission, plasticity of neuronal membranes, the function of receptors.
Pharmacokinetics
Absorption and distribution After ingestion, absorption is 88%. It easily penetrates the BBB, the concentration in the brain reaches 45% level in the blood plasma. Metabolism and elimination Biologically transforms choline and glycerophosphate (providing the pharmacological effects of the drug) into the body of choline alfoscerate. 85% is excreted by the lungs in the form of carbon dioxide; the rest (15%) is excreted in the urine and feces.
Indications
Acute and recovery periods of severe head injury and ischemic stroke, recovery period of hemorrhagic stroke,flowing with focal hemispheric symptoms or symptoms of brain stem damage, psychoorganic syndrome on the background of degenerative and involutional changes in the brain, chronic cerebral circulatory insufficiency, cognitive disorders (mental function disorders, memory, confusion, disorientation, reduced motivation, initiative and concentration) including with dementia and encephalopathy; senile pseudomelancholia.
Contraindications
Hypersensitivity; pregnancy; breastfeeding.
Use during pregnancy and lactation
The drug is contraindicated for use during pregnancy and lactation (breastfeeding). In experimental studies have not been identified mutagenic and teratogenic effects of the drug, as well as the effect on reproductive function.
Dosage and administration
In acute conditions, the drug is administered intramuscularly or intravenously (slowly) in a daily dose of 1 g (1 ampoule) for 10-15 days, then transferred to the oral administration of the drug in a daily dose of 1.2 g (800 mg / 2 caps. / in the morning and 400 mg / 1 caps / day) for 6 months. In chronic conditions: orally 0.4 g (1 caps) 3 times a day, preferably before meals. The duration of treatment is 3-6 months.
Side effects
Allergic reactions, nausea (due to dopaminergic activation).
Overdose
Symptoms: dyspepsia. Treatment: gastric lavage, taking activated charcoal, symptomatic therapy.
Interaction with other drugs
Drug interaction drug Cerepro is not installed.
special instructions
If nausea occurs after taking the drug, the dose should be reduced. Influence on the ability to drive vehicles and control mechanisms Cerepro does not affect the speed of psychomotor reactions.